BRAF (mutated V600E) Antibody (Mouse mAb) [M8P1]

CatNo: F2152

    Application: Reactivity:
    • Lane 1: A375
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:1000
    Application
    WB, IHC
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    84 kDa 85 kDa,36 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human melanoma; Caco-2 cells; A375 cells
    ネガティブコントロール HCT 116 cells; SW480 cells; Caco-2 cells; HT-29 cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    BRAF (mutated V600E) Antibody (Mouse mAb) [M8P1] detects endogenous levels of total BRAF protein only when muted at V600E.
    タンパク質の局在
    細胞膜、細胞質、細胞内膜系、細胞核
    Uniprot ID
    P15056
    Clone
    M8P1
    Synonym(s)
    BRAF1, RAFB1, BRAF, Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1
    Background
    BRAF V600E is an oncogenic variant of the RAF family serine/threonine kinase BRAF in which a valine-to-glutamate substitution at codon 600 within the activation segment of the kinase domain produces a constitutively active enzyme that persistently drives MAPK/ERK signaling independently of upstream RAS input. The kinase retains the typical regulatory and catalytic architecture of RAF proteins, including an N‑terminal RAS-binding and regulatory region and a C‑terminal kinase domain; the V600E change mimics phosphorylation within the activation segment, stabilizing the active conformation, increasing kinase activity by several hundred‑fold compared with wild-type BRAF, and favoring monomeric signaling that potently phosphorylates MEK1/2. Sustained MEK–ERK activation by BRAF V600E alters transcription of genes that control proliferation, differentiation and apoptosis and promotes melanocyte survival and cell-cycle progression through upregulation of cyclin D1, downregulation of p27^Kip1 and modulation of pro- and anti-apoptotic factors, while also impacting senescence programs and cooperating with additional lesions to overcome oncogene-induced growth arrest during melanomagenesis. BRAFV600E reshapes chromatin and gene expression patterns, with widespread changes in genes linked to cell adhesion, invasion, immune evasion and cytokine signaling, indicating that the mutation drives proliferation and also remodels the tumor microenvironment and metastatic behavior through MAPK-dependent transcriptional programs. In melanoma, activating BRAF mutations occur in about half of cases, and more than 90% of these involve V600E, defining a major molecular subset with characteristic clinicopathological features and strong dependence on MAPK signaling. BRAF V600E is also present in a distinct subgroup of colorectal cancers arising through the serrated pathway, where it appears early in tumorigenesis and associates with high-level microsatellite instability, CpG island methylator phenotype and right-sided colon location, and these tumors often exhibit poor prognosis and reduced benefit from standard anti-EGFR therapies due to MAPK pathway dominance. BRAF V600E in colorectal cancer intersects with WNT signaling, augmenting WNT activity in the absence of common APC mutations and relying on RNF43 and other alterations to sustain β‑catenin–driven transcription, highlighting cross-talk between MAPK and WNT cascades in this aggressive subtype. The central role of BRAF V600E in MAPK pathway activation has made it a key therapeutic target, and selective inhibitors such as vemurafenib and dabrafenib, often combined with MEK inhibitors, produce significant tumor regressions in BRAF V600-mutant melanoma and metastatic colorectal cancer, while acquired resistance frequently involves reactivation of MAPK signaling via secondary RAS/RAF alterations or activation of parallel pathways such as PI3K.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください